Integrated, cross-sectoral psycho-oncology (isPO): a new form of care for newly diagnosed cancer patients in Germany.
Cancer
Complex intervention
Dissemination
Implementation
Practice-based research
Psycho-oncology
Quality improvement
Stepped-care
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
22 Apr 2022
22 Apr 2022
Historique:
received:
03
12
2020
accepted:
15
03
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
27
4
2022
Statut:
epublish
Résumé
The annual incidence of new cancer cases has been increasing worldwide for many years, and is likely to continue to rise. In Germany, the number of new cancer cases is expected to increase by 20% until 2030. Half of all cancer patients experience significant emotional and psychosocial distress along the continuum of their disease, treatment, and aftercare, and also as long-term survivors. Consequently, in many countries, psycho-oncological programs have been developed to address this added burden at both the individual and population level. These programs promote the active engagement of patients in their cancer therapy, aftercare and survivorship planning and aim to improve the patients' quality of life. In Germany, the "new form of care isPO" ("nFC-isPO"; integrated, cross-sectoral psycho-oncology/integrierte, sektorenübergreifende Psycho-Onkologie) is currently being developed, implemented and evaluated. This approach strives to accomplish the goals devised in the National Cancer Plan by providing psycho-oncological care to all cancer patients according to their individual healthcare needs. The term "new form of care" is defined by the Innovation Fund (IF) of Germany's Federal Joint Committee as "a structured and legally binding cooperation between different professional groups and/or institutions in medical and non-medical care". The nFC-isPO is part of the isPO project funded by the IF. It is implemented in four local cancer centres and is currently undergoing a continuous quality improvement process. As part of the isPO project the nFC-isPO is being evaluated by an independent institution: the Institute for Medical Sociology, Health Services Research, and Rehabilitation Science (IMVR), University of Cologne, Germany. The four-year isPO project was selected by the IF to be eligible for funding because it meets the requirements of the federal government's National Cancer Plan (NCP), in particular, the "further development of the oncological care structures and quality assurance" in the psycho-oncological domain. An independent evaluation is required by the IF to verify if the new form of care leads to an improvement in cross-sectoral care and to explore its potential for permanent integration into the German health care system. The nFC-isPO consists of six components: a concept of care (C1), care pathways (C2), a psycho-oncological care network (C3), a care process organization plan (C4), an IT-supported documentation and assistance system (C5) and a quality management system (C6). The two components concept of care (C1) and care pathways (C2) represent the isPO clinical care program, according to which the individual cancer patients are offered psycho-oncological services within a period of 12 months after program enrolment following the diagnosis of cancer. The remaining components (C3-C6) represent the formal-administrative aspects of the nFC-isPO that are intended to meet the legally binding requirements of patient care in the German health care system. With the aim of systematic development of the nFC-isPO while at the same time enabling the external evaluators to examine its quality, effectiveness and efficiency under conditions of routine care, the project partners took into consideration approaches from translational psycho-oncology, practice-based health care research and program theory. In order to develop a structured, population-based isPO care program, reference was made to a specific program theory, to the stepped-care approach, and also to evidence-based guideline recommendations. The basic version, nFC-isPO, was created over the first year after the start of the isPO project in October 2017, and has since been subject to a continuous quality improvement process. In 2019, the nFC-isPO was implemented at four local psycho-oncological care networks in the federal state North Rhine-Westphalia, in Germany. The legal basis of the implementation is a contract for "special care" with the German statutory health insurance funds according to state law (§ 140a SCB V; Social Code Book V for the statutory health insurance funds). Besides the accompanying external evaluation by the IMVR, the nFC-isPO is subjected to quarterly internal and cross-network quality assurance and improvement measures (internal evaluation) in order to ensure continuous quality improvement process. These quality management measures are developed and tested in the isPO project and are to be retained in order to ensure the sustainability of the quality of nFC-isPO for later dissemination into the German health care system. Demands on quality, effectiveness and cost-effectiveness of in the German health care system are increasing, whereas financial resources are declining, especially for psychosocial services. At the same time, knowledge about evidence-based screening, assessment and intervention in cancer patients and about the provision of psychosocial oncological services is growing continuously. Due to the legal framework of the statutory health insurance in Germany, it has taken years to put sound psycho-oncological findings from research into practice. Ensuring the adequate and sustainable financing of a needs-oriented, psycho-oncological care approach for all newly diagnosed cancer patients, as required by the NCP, may still require many additional years. The aim of the isPO project is to develop a new form of psycho-oncological care for the individual and the population suffering from cancer, and to provide those responsible for German health policy with a sound basis for decision-making on the timely dissemination of psycho-oncological services in the German health care system. The study was pre-registered at the German Clinical Trials Register (https://www.drks.de/DRKS00015326) under the following trial registration number: DRKS00015326 ; Date of registration: October 30, 2018.
Sections du résumé
BACKGROUND
BACKGROUND
The annual incidence of new cancer cases has been increasing worldwide for many years, and is likely to continue to rise. In Germany, the number of new cancer cases is expected to increase by 20% until 2030. Half of all cancer patients experience significant emotional and psychosocial distress along the continuum of their disease, treatment, and aftercare, and also as long-term survivors. Consequently, in many countries, psycho-oncological programs have been developed to address this added burden at both the individual and population level. These programs promote the active engagement of patients in their cancer therapy, aftercare and survivorship planning and aim to improve the patients' quality of life. In Germany, the "new form of care isPO" ("nFC-isPO"; integrated, cross-sectoral psycho-oncology/integrierte, sektorenübergreifende Psycho-Onkologie) is currently being developed, implemented and evaluated. This approach strives to accomplish the goals devised in the National Cancer Plan by providing psycho-oncological care to all cancer patients according to their individual healthcare needs. The term "new form of care" is defined by the Innovation Fund (IF) of Germany's Federal Joint Committee as "a structured and legally binding cooperation between different professional groups and/or institutions in medical and non-medical care". The nFC-isPO is part of the isPO project funded by the IF. It is implemented in four local cancer centres and is currently undergoing a continuous quality improvement process. As part of the isPO project the nFC-isPO is being evaluated by an independent institution: the Institute for Medical Sociology, Health Services Research, and Rehabilitation Science (IMVR), University of Cologne, Germany. The four-year isPO project was selected by the IF to be eligible for funding because it meets the requirements of the federal government's National Cancer Plan (NCP), in particular, the "further development of the oncological care structures and quality assurance" in the psycho-oncological domain. An independent evaluation is required by the IF to verify if the new form of care leads to an improvement in cross-sectoral care and to explore its potential for permanent integration into the German health care system.
METHODS
METHODS
The nFC-isPO consists of six components: a concept of care (C1), care pathways (C2), a psycho-oncological care network (C3), a care process organization plan (C4), an IT-supported documentation and assistance system (C5) and a quality management system (C6). The two components concept of care (C1) and care pathways (C2) represent the isPO clinical care program, according to which the individual cancer patients are offered psycho-oncological services within a period of 12 months after program enrolment following the diagnosis of cancer. The remaining components (C3-C6) represent the formal-administrative aspects of the nFC-isPO that are intended to meet the legally binding requirements of patient care in the German health care system. With the aim of systematic development of the nFC-isPO while at the same time enabling the external evaluators to examine its quality, effectiveness and efficiency under conditions of routine care, the project partners took into consideration approaches from translational psycho-oncology, practice-based health care research and program theory. In order to develop a structured, population-based isPO care program, reference was made to a specific program theory, to the stepped-care approach, and also to evidence-based guideline recommendations.
RESULTS
RESULTS
The basic version, nFC-isPO, was created over the first year after the start of the isPO project in October 2017, and has since been subject to a continuous quality improvement process. In 2019, the nFC-isPO was implemented at four local psycho-oncological care networks in the federal state North Rhine-Westphalia, in Germany. The legal basis of the implementation is a contract for "special care" with the German statutory health insurance funds according to state law (§ 140a SCB V; Social Code Book V for the statutory health insurance funds). Besides the accompanying external evaluation by the IMVR, the nFC-isPO is subjected to quarterly internal and cross-network quality assurance and improvement measures (internal evaluation) in order to ensure continuous quality improvement process. These quality management measures are developed and tested in the isPO project and are to be retained in order to ensure the sustainability of the quality of nFC-isPO for later dissemination into the German health care system.
DISCUSSION
CONCLUSIONS
Demands on quality, effectiveness and cost-effectiveness of in the German health care system are increasing, whereas financial resources are declining, especially for psychosocial services. At the same time, knowledge about evidence-based screening, assessment and intervention in cancer patients and about the provision of psychosocial oncological services is growing continuously. Due to the legal framework of the statutory health insurance in Germany, it has taken years to put sound psycho-oncological findings from research into practice. Ensuring the adequate and sustainable financing of a needs-oriented, psycho-oncological care approach for all newly diagnosed cancer patients, as required by the NCP, may still require many additional years. The aim of the isPO project is to develop a new form of psycho-oncological care for the individual and the population suffering from cancer, and to provide those responsible for German health policy with a sound basis for decision-making on the timely dissemination of psycho-oncological services in the German health care system.
TRIAL REGISTRATION
BACKGROUND
The study was pre-registered at the German Clinical Trials Register (https://www.drks.de/DRKS00015326) under the following trial registration number: DRKS00015326 ; Date of registration: October 30, 2018.
Identifiants
pubmed: 35459202
doi: 10.1186/s12913-022-07782-0
pii: 10.1186/s12913-022-07782-0
pmc: PMC9034572
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
543Subventions
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Organisme : Federal Joint Committee (G-BA)
ID : 01NVF17022
Informations de copyright
© 2022. The Author(s).
Références
Public Health Genomics. 2016;19(3):178-86
pubmed: 27238357
Psychooncology. 2009 Jan;18(1):6-13
pubmed: 19097140
BMJ. 2020 Mar 31;368:m865
pubmed: 32234777
Eur J Cancer. 1994;30A(1):37-40
pubmed: 8142161
J Consult Clin Psychol. 2013 Apr;81(2):318-35
pubmed: 22663900
BMC Fam Pract. 2014 May 13;15:94
pubmed: 24885266
CA Cancer J Clin. 2019 Jan;69(1):35-49
pubmed: 30376182
Palliat Support Care. 2019 Jun;17(3):253-261
pubmed: 29880068
J Clin Oncol. 2013 Feb 20;31(6):782-93
pubmed: 23319686
Lancet Oncol. 2015 Sep;16(12):1231-72
pubmed: 26431866
J Cancer Surviv. 2020 Dec;14(6):826-833
pubmed: 32514909
Psychother Psychosom Med Psychol. 2015 May;65(5):177-82
pubmed: 25485601
J Oncol. 2020 May 07;2020:7432849
pubmed: 32454826
J Psychosom Res. 2011 Aug;71(2):74-8
pubmed: 21767686
BMC Psychiatry. 2020 Mar 23;20(1):131
pubmed: 32293366
J Clin Oncol. 2012 Apr 10;30(11):1154-9
pubmed: 22412134
Psychooncology. 2011 Jul;20(7):677-80
pubmed: 21710503
Psychooncology. 2017 Jul;26(7):917-926
pubmed: 27440317
J Natl Compr Canc Netw. 2013 May;11(5 Suppl):687-9
pubmed: 23704244
BMC Fam Pract. 2009 Aug 23;10:58
pubmed: 19698153
J Clin Oncol. 2014 Nov 1;32(31):3540-6
pubmed: 25287821
Psychooncology. 2018 Oct;27(10):2310-2316
pubmed: 29980165
J Oncol Pract. 2015 Jan;11(1):e103-9
pubmed: 25352389
Ann Oncol. 2016 Sep;27(9):1754-60
pubmed: 27287209
Support Care Cancer. 2011 Dec;19(12):1899-908
pubmed: 21898134
Psychooncology. 2011 Jun;20(6):572-84
pubmed: 21442689
HNO. 2016 Jul;64(7):515-6
pubmed: 26801892
Support Care Cancer. 2020 Jan;28(1):211-220
pubmed: 31001695
Psychol Health. 2019 Jan;34(1):44-63
pubmed: 30516396
Cancers (Basel). 2020 Apr 19;12(4):
pubmed: 32325878
JAMA. 2007 Jan 24;297(4):403-6
pubmed: 17244837
BMC Cancer. 2017 Dec 14;17(1):850
pubmed: 29241445
Psychooncology. 2019 Jul;28(7):1394-1407
pubmed: 31077475
J Natl Compr Canc Netw. 2019 Oct 1;17(10):1251-1256
pubmed: 31590156
Psychooncology. 2020 Dec;29(12):1982-1987
pubmed: 32390322
J Health Psychol. 2020 Jan;25(1):7-25
pubmed: 29260595
Epidemiol Psychiatr Sci. 2020 Jan 09;29:e85
pubmed: 31915097
Gesundheitswesen. 2015 Sep;77 Suppl 1:S141-2
pubmed: 24937351
J Natl Compr Canc Netw. 2010 Apr;8(4):487-94
pubmed: 20410338
Med J Aust. 2009 Apr 6;190(S7):S94-8
pubmed: 19351302
BMJ Open. 2020 Feb 28;10(2):e034178
pubmed: 32114472
EPMA J. 2010 Dec;1(4):535-47
pubmed: 23199108
Z Evid Fortbild Qual Gesundhwes. 2018 Feb;130:8-12
pubmed: 28935458
Dtsch Med Wochenschr. 2018 Mar;143(5):316-323
pubmed: 29506298
J Clin Oncol. 2007 Oct 10;25(29):4670-81
pubmed: 17846453
J Affect Disord. 2010 Nov;126(3):335-48
pubmed: 20207007
Support Care Cancer. 2010 Oct;18(10):1241-62
pubmed: 20596731
Psychooncology. 2012 Oct;21(10):1027-33
pubmed: 23027723
Br J Cancer. 2009 Mar 24;100(6):908-12
pubmed: 19240713
Psychooncology. 2019 Jan;28(1):61-67
pubmed: 30286522
Dtsch Med Wochenschr. 2014 Nov;139(46):2357-60
pubmed: 25369048
Prev Sci. 2013 Aug;14(4):319-51
pubmed: 23430579
Psychooncology. 2017 Aug;26(8):1191-1197
pubmed: 27723939
Gen Hosp Psychiatry. 1997 May;19(3):169-78
pubmed: 9218985
J Clin Oncol. 2015 Nov 10;33(32):3817-25
pubmed: 26304871
Oncotarget. 2017 May 30;8(22):36800-36811
pubmed: 28404938
Behav Med. 2021 Jul-Sep;47(3):214-224
pubmed: 32275195
Disabil Rehabil. 2020 Apr;42(8):1062-1070
pubmed: 30497305
Psychooncology. 2012 Mar;21(3):229-38
pubmed: 21919120
Psychooncology. 2019 Sep;28(9):1862-1870
pubmed: 31257660
Healthcare (Basel). 2016 Aug 10;4(3):
pubmed: 27517969
Depress Anxiety. 2020 Sep;37(9):908-915
pubmed: 32485033
Psychooncology. 2015 Apr;24(4):365-70
pubmed: 25858439
Psychooncology. 2016 Dec;25(12):1380-1392
pubmed: 26810383
JAMA. 2012 Jul 18;308(3):243-4
pubmed: 22797640
Eur J Haematol. 2017 Nov;99(5):423-430
pubmed: 28833529
Psychooncology. 2017 Mar;26(3):354-360
pubmed: 27151147
Psychooncology. 2006 Jun;15(6):541-6
pubmed: 16331595
Support Care Cancer. 2018 May;26(5):1585-1595
pubmed: 29199362
BMC Cancer. 2018 Nov 7;18(1):1077
pubmed: 30404619
PLoS One. 2018 Oct 4;13(10):e0205160
pubmed: 30286172
Support Care Cancer. 2011 Aug;19(8):1097-105
pubmed: 21494781
J Cancer Surviv. 2019 Oct;13(5):695-702
pubmed: 31347010
J Clin Oncol. 2014 May 20;32(15):1605-19
pubmed: 24733793
J Eval Clin Pract. 2018 Feb;24(1):269-277
pubmed: 28032412
Clin Nurs Res. 2019 Nov;28(8):968-991
pubmed: 29726271
Psychooncology. 2018 Jan;27(1):75-82
pubmed: 28568377
J Behav Med. 2016 Dec;39(6):935-946
pubmed: 27515801
J Eval Clin Pract. 2018 Feb;24(1):266-268
pubmed: 29589876
Support Care Cancer. 2017 Nov;25(11):3447-3456
pubmed: 28667564
Curr Oncol. 2015 Oct;22(5):315-6
pubmed: 26628863
Eur J Cancer Care (Engl). 2010 Jul;19(4):522-9
pubmed: 20030697
Psychooncology. 2018 Dec;27(12):2847-2854
pubmed: 30276915
J Natl Compr Canc Netw. 2012 Oct 1;10 Suppl 1:S1-9
pubmed: 23042831
Psychooncology. 2016 May;25(5):482-90
pubmed: 27092813
Psychooncology. 2018 Apr;27(4):1150-1161
pubmed: 29361206
Jt Comm J Qual Saf. 2003 Nov;29(11):563-74
pubmed: 14619349
Eur J Cancer. 2017 Feb;72:46-53
pubmed: 28024266
Cancer. 2009 Sep 15;115(18 Suppl):4419-29
pubmed: 19731353
Psychooncology. 2011 Nov;20(11):1221-7
pubmed: 20878724
Adv Health Care Manag. 2013;15:3-26
pubmed: 24749211
Psychooncology. 2019 Jan;28(1):3-10
pubmed: 30440112
BMJ Support Palliat Care. 2020 Dec;10(4):e36
pubmed: 30981992
Int J Methods Psychiatr Res. 2020 Jun;29(2):e1821
pubmed: 32090408
Br J Psychiatry. 2005 Jan;186:11-7
pubmed: 15630118
Psychooncology. 2019 Feb;28(2):415-422
pubmed: 30512208
Health Syst Transit. 2014;16(2):1-296, xxi
pubmed: 25115137
Psychother Psychosom Med Psychol. 2013 Dec;63(12):466-72
pubmed: 23828217
Psychooncology. 2019 Feb;28(2):351-357
pubmed: 30466146
J Psychosom Res. 2007 Jul;63(1):83-91
pubmed: 17586341
Psychooncology. 2017 Apr;26(4):419-423
pubmed: 28398012
Behav Med. 2012;38(3):90-114
pubmed: 22873734
Milbank Q. 2004;82(4):581-629
pubmed: 15595944
Gen Hosp Psychiatry. 2006 Jan-Feb;28(1):55-8
pubmed: 16377366
Perspect Psychol Sci. 2015 May;10(3):328-45
pubmed: 25987511
Psychooncology. 2015 Sep;24(9):987-1001
pubmed: 26268799
Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1029-36
pubmed: 27371756
Support Care Cancer. 2016 Jan;24(1):33-41
pubmed: 25903929
J Clin Oncol. 2012 Apr 10;30(11):1178-86
pubmed: 22412139
Osong Public Health Res Perspect. 2019 Dec;10(6):385-393
pubmed: 31897368
Support Care Cancer. 2020 Aug;28(8):3921-3926
pubmed: 31858249
Psychooncology. 2015 Nov;24(11):1514-20
pubmed: 25946724
BMJ Open. 2020 Mar 9;10(3):e034141
pubmed: 32156765
Genet Med. 2007 Oct;9(10):665-74
pubmed: 18073579
Epidemiol Psychiatr Sci. 2020 Jan 09;29:e86
pubmed: 31915100
J Clin Transl Sci. 2017 Feb;1(1):60-66
pubmed: 28480056
J Health Polit Policy Law. 2001 Oct;26(5):1165-77
pubmed: 11765263
Patient Educ Couns. 2017 Oct;100(10):1934-1942
pubmed: 28592366
Genomics Proteomics Bioinformatics. 2003 May;1(2):87-9
pubmed: 15626338
Lancet Oncol. 2011 Feb;12(2):160-74
pubmed: 21251875
Qual Assur. 1991 Oct;1(1):4-9
pubmed: 1669967
Ecancermedicalscience. 2018 Sep 25;12:873
pubmed: 30483353
J Korean Acad Nurs. 2019 Jun;49(3):298-306
pubmed: 31266926
JAMA. 1988 Sep 23-30;260(12):1743-8
pubmed: 3045356
Transl Behav Med. 2017 Dec;7(4):648-656
pubmed: 28101728
Z Arztl Fortbild Qualitatssich. 2002 Feb;96(2):91-6
pubmed: 11921611
J Psychosom Res. 1997 Jan;42(1):17-41
pubmed: 9055211
Psychooncology. 2019 Nov;28(11):2119-2140
pubmed: 31475766
Health Promot Int. 2006 Sep;21(3):245-55
pubmed: 16751630